Development of a Clinical Research Project Comparing Infection Risk Assessment Scores in Oncology

AUTHORS: REBECCA DOVE, MPH, HELENE FULD FELLOW¹; BRENDA SHELTON DNP, RN, APRN-CNS, CCRN, AOCN^{1,2}

JOHNS HOPKINS UNIVERSITY SCHOOL OF NURSING¹, SIDNEY KIMMEL CANCER CENTER AT JOHNS HOPKINS²; BALTIMORE, MD

Problem

- Sepsis is the leading cause of nonmalignant death in oncology patients^{1,2}. Approximately 14% of oncology patients develop sepsis.
 Sepsis-related mortality rate in this patient population is estimated to be 30-40%^{1,3}.
- Early sepsis detection results in better patient outcomes. Multiple sepsis screening tools exist, but none are validated specifically for oncology patients. Hospital-wide sepsis screening methods over diagnose sepsis, and research suggests that the universal screening criteria should be updated⁴.
- The MASCC score is recommended to predict sepsis in oncology patients. It is only validated in febrile neutropenic patients and not all oncological populations ^{1,5}.

2 Long Term Objectives:

- Primary Aim: Evaluate MASCC's sensitivity and specificity to predict severe sepsis or septic shock in ambulatory oncology patients who screen positive for sepsis.
- **Secondary Aim:** Analyze subpopulations for which the MASCC Risk score has not been validated to evaluate potential application.

Short Term Objective:

 Conduct review of current evidence to determine which variables and screening tools should be studied. Findings were utilized to draft and submit an IRB proposal to compare and correlate variables and tools supporting prediction of sepsis outcomes in patients with cancer.

3 Literature Review

A review of current literature was done to update a previous review from 2013⁴. PubMed, EMBASE, Cochrane, CINAHL, and Guidelines.gov were used to search for qSOFA, SOFA, MASCC, and Sepsis screening related articles published since March 2014 to determine appropriate variables. Based on the review and current JHH practices it was concluded that three scoring systems should be compared with MASCC results:

- validated in powered study⁶
- qSOFA Low sensitivity, high specificity⁷
- **Surviving Sepsis** Poor sensitivity & specificity⁴

Table 1. Sepsis screening score criteria.

Parameter	Surviving Sepsis ⁴	JHH ⁶	qSOFA ⁷	
Temperature	T < 36.0°C or > 38.3°C	T < 35.5 °C (with out symptoms) or > 38.0 °C		
Heart Rate	HR > 90 bpm	HR > 100 bpm		
Respiratory Rate	RR > 20/min	RR> 20/min	RR > 21/min	
Blood Pressure	SBP < 90 mmHg or > 40 mmHg drop from baseline, or MAP < 65 mmHg	SBP < 90 mmHg or > 40 mmHg drop from baseline, or MAP < 65 mmHg	Systolic BP < 100 mmHg	
WBC	< 4000 mm ³ or > 12,000mm ³ or > 10% bands	< 4000 mm ³ or > 12,000mm ³ or > 10% bands, neutropenia		
Other	None	Glucose > 140 mg/dL in absence of diabetes	Mental status changes	
Positive Screen	Any two of the above parameters plus risk of infection			

Variable Selection: based on the sepsis screening tools, MASCC screening tool, and data indicating patients' infection status and oncology treatment.

Table 2. Variable selection rationale

Variable	Rationale	Literature
Oncology diagnosis and treatment type	No currently validated sepsis screening tools for general oncology patient populations.	Shelton, 2016 ⁴
Sepsis screen data: JHH, qSOFA, Surviving Sepsis score	All three scores needed to determine which was most efficient when compared to the MASCC risk score.	
MASCC Screening Data: illness burden, hypotension, COPD, malignancy without prior fungal infection, dehydration, outpatient status, and age.	Necessary to calculate MASCC scores for each participant. These are independent factors that predict level of risk in febrile neutropenic oncology patients.	Klastersky et al., 2000 ¹²
Patient outcome data: Severe Sepsis, Septic Shock, and Survival Status	These data will support or contradict the predictive screening tests. Similar methods were used when validating MASCC scores.	Klastersky, 2000; Shelton, 2016; Ahn et al., 2012; Baskaran et al., 2008; Feld et al., 2002; Klastersky & Paesamans,20 13 5,4,9,10,11,12
Laboratory values: serum lactate, serum creatinine, bilirubin	Strong predictors of sepsis severity and mortality. Indicates accuracy of the screening tools.	Dellinger et al., 2013 ⁶
Infection Variables: source, positive culture, antibiotics	Provide evidence of true infection. Utilized in similar studies.	Kim et al., 2017 ⁷

- Methods: Prospective chart review of all patients seen in the ambulatory Hematology-Oncology Clinic or the Weinberg Urgent Care Clinic.
 - Numerator data: 3660 patient encounters during which patients display signs of sepsis
 - Denominator data: all clinic visits.

Table 3. Study question and associated tests

- Tuble 3. Study question and associated tests			
Question	Test		
How do sepsis screen positivity and MASCC risk scores compare to incidence of severe sepsis or septic shock?	Correlational statistics to validate MASCC score's prediction of severe sepsis		
How does the MASCC risk score compare to the three sepsis screen positive scores for predictive value? • Specific focus: appropriateness for use of the MASCC score to predict outcomes for ambulatory oncology patients regardless of febrile neutropenia	 Sensitivity Specificity Positive predictive value/negative predictive value Receiver Operating Characteristic (ROC) curves ANOVA and Multiple Regression compare MASCC score with other sepsis positive criteria 		

ROC Curve: The ROC statistic allows for comparison of different tools' sensitivity and specificity. The area under ROC curves indicates the accuracy of MASCC⁸. These AUC statistics will be compared between tools to determine relative accuracy as is seen in other literature⁷.

5 Timeline

- Literature review; consult with experts in oncology, infectious disease and statistics
- Observed current practices in the ambulatory clinics and discussed with unit leadership
- Submitted application to the Oncology
 Nursing Research Committee. After revisions,
 received final approval
- Submitted and received Shirley Sohmer Research Grant
- Drafted outcomes assessment and data collection tools
- Submitted project to Hospital Nursing Research Committee
- Completed IRB required modules, drafted IRB application and submitted project

6 Lessons Learned

- Additional research was needed to determine the best way to record lab culture data that was drawn at the initial screen and what to use as time zero.
- Approval was required by the Oncology Nursing Research Committee, Hospital Nursing Research Committee, and the IRB prior to beginning the research
 - Provided multiple sources of input
 - Delayed data collection.

7 References

1. Baden, .R., Swaminathan, S, Angarone, M., Blouin, G., Camins, B.C., Casper, C.,... Wilson, J.W. (2017) Prevention and treatment of cancer-related infections, version 2.2017. Retrieved from: www.nccn.org.

2. Mariotte, E., Canet, E., Debrumetz, A., Lemiale, V., Seguin, A., Darmon, M., Schlemmer, B., & Azoulay, E. (2012). Survival in neutropenic patients with severe sepsis or septic shock. *Critical Care Medicine*, 40(1). 4349.

3. Young, R.S., Gobel, B.H., Schumacher, M., Lee, J., Weaver, C., Weitzman, S. (2014). Use of the modified

early warning score and serum lactate to prevent cardiopulmonary arrest in hematology-oncology patients: a quality improvement study. *American Journal Medical Quality, 29*(6), 530-53.

4. Shelton, B.K., Stanik-Hutt, J., Kane, J., & Jones, R.J. (2016) Implementing Surviving Sepsis Campaign "First Six Hours Bundled Interventions" In an Ambulatory Clinic for Patients with Hematologic Malignancies. *Clinical*

Journal of Oncology Nursing, 20(3), 281-288.

5. Klastersky, J., Paesmans, M., Rubenstein, E.B., Boyer, M., Elting, L., Feld, R., ... Talcott, J. (2000). The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for

identifying low-risk febrile neutropenic cancer patients. Journal Clinical Oncology, 18, 3038-3051.

6. Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M..... The Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. (2013). Surviving Sepsis Campaign: International Guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Medicine*, 39, 165-228.

7. Kim, M., Ahn, S., Kim, W.YY., Sohn, C.H., Seo, D.W., Lee, Y., & Lim, K.2017. Predictive performance of the quick Sequential Organ Failure Assessment score as a screening tool for sepsis, mortality, and intensive care unit admissions in patients. Support Cancer Care 25. doi 10.1007/s00520-016-3567-6

8. Florkowski, C.M. (2008). Sensitivity, Specificity, Receiver-Operating Characteristic (ROC) Curves and Likelihood Ratios: Communicating the Performance of Diagnostic Tests.

Likelihood Ratios: Communicating the Performance of Diagnostic Tests.

9. Ahn, S., Lee, Y.S. (2012). Predictive factors for poor prognosis febrile neutropenia. *Current Options in*

Oncology, 24, 376-380. doi: 10.1097/CCO.0b013e328352ead2

10. Baskaran, N.D., Gan, G.G., & Adeeba, K. (2008). Applying the Multinational Association for Supportive Care in cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. *Annals Hematology*, 87(7), 563-569. doi: 10.1007/s00277-008-0487-7

11. Feld, R., Paesmans, M., Freifeld, A.G., Klastersky, J., Pizzo, P.A., Rubenstein, E., Talcott, J.A. ... Multinational Association for Supportive Care in Cancer. (2002). Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the immunocompromised host Society/ Multinational Association for Supportive Care in Cancer, with an emphasis on outpatient studies. *Clinical Infectious Disease*, 35(12), 1463-1468.

12. Klastersky, J., & Paesmans, M., & Rubenstein, E. (2013). The multinational association for supportive care in cancer risk score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. *Supportive Care in Cancer*, 21(5), 3038-3050

Funding Source: The Helene Fuld Leadership Program for the Advancement of Patient Care Quality and Safety



JOHNS HOPKINS
SCHOOL of NURSING